Poseida Therapeutics Inc. PSTX stock dropped about 34.5% in the after-hours trading on Monday, after a patient died in a prostate cancer drug trial, according to a filing the company made with the United States Securities and Exchange Commission.
What Happened
The trial was carried out in July on a patient that failed prior treatments with multiple anti-cancer agents and was being treated with the drugmaker’s P-PSMA-101, according to Poseida.
The company said that the U.S. Food and Drug Administration has ordered a pause to the trial in order to investigate the death.
Why It Matters
The San Diego-based drugmaker announced the pricing of its IPO at $16 per share in early July. The gross proceeds from the offer were expected to be $224 million at the time.
The company concluded its latest funding round in June and has raised $336.5 million to date, from lead investors such as Novartis AG NVS, as per Crunchbase.
Price Action
Poseida shares traded nearly 34.5% lower at $8.51 in the after-hours session after the news of the drug trial became public on Monday. The shares had closed the regular session nearly 0.8% lower at $13.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.